NCT02546284View on ClinicalTrials.gov

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions

Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG

lenzilumab

Trial Locations (2)

33612

Moffitt Cancer Center, Tampa

55905

Mayo Clinic Cancer Center Clinical Research, Rochester

Sponsors

Lead Sponsor

Humanigen, Inc.

All Listed Sponsors

lead

Humanigen, Inc.

INDUSTRY